Premarin Vaginal Cream is a prescription vaginal estrogen product used after menopause for vulvar and vaginal atrophy symptoms such as dryness, burning, itching, and pain with sex. Its goal is to restore the estrogen effect locally in vaginal tissues so they become less dry and fragile.
Even though you apply it in the vagina, systemic absorption can still occur, meaning a portion may enter the bloodstream. Because of that, the FDA labeling says the warnings, precautions, and adverse reactions associated with oral Premarin should be considered with the vaginal cream as well.
This article focuses on which Premarin cream side effects can be watched at home, and which symptoms should push you to call your clinician or seek urgent help.
Why side effects can happen with Premarin cream
After menopause, vaginal tissue can become thinner, drier, and easier to irritate. When you reintroduce estrogen, the tissue begins changing again. That transition period can feel like burning, stinging, itching, or extra discharge for some people.
Systemic absorption can also occur with Premarin Vaginal Cream. That is why warnings about blood clots, stroke, gallbladder problems, and other estrogen-related risks show up in postmarketing reports even though the product is used vaginally or topically.
Studies on vaginal estrogens overall often find low systemic levels compared with oral therapy. For example, a study showed that oral estrogen increased estradiol up to 25 times above baseline, while vaginal estrogen increased it about 6 times. So absorption does happen, but the overall systemic exposure is lower than with pills.
Importantly, most women using vaginal estrogen had estradiol levels that stayed within the normal postmenopausal range (0-50 pg/mL). Peak estradiol levels increased to about 12.8 pg/mL with vaginal use compared to 19.4 pg/mL with oral use.
The good news is that large observational studies did not see higher rates of cardiovascular disease or cancer among vaginal estrogen users compared with non-users.
Researchers analyzed data from 45,663 postmenopausal women in the Women’s Health Initiative Observational Study, with a follow-up of 7.2 years. Among women with an intact uterus, vaginal estrogen users did not have higher risks of stroke, breast cancer, colorectal cancer, endometrial cancer, or blood clots compared with nonusers, and they actually had a 32% lower risk of major health events.
In women who had undergone hysterectomy (surgery to remove the uterus), there were no significant differences in risks of cardiovascular disease, cancer, or death between users and nonusers.
However, these findings do not eliminate individual risk factors, so it is still important to know the possible side effects of Premarin, including rare ones.
Common side effects of Premarin cream
Even though these are common, they can still be worth discussing with your prescriber, especially if they affect quality of life.
-
- Vaginal burning, irritation, and itching after insertion
- Increased white or clear vaginal discharge that may be normal (leukorrhea)
- Unexpected or irregular vaginal bleeding (metrorrhagia)
- Vaginitis and yeast infection
- Mild urinary symptoms like painful or uncomfortable urination (dysuria)
- Headache
- Pelvic pain
- Flushing or vasodilation
- Breast pain or tenderness
If a symptom is mild, getting better within 1 to 2 weeks, and you otherwise feel well, you can monitor it at home and bring it up at your next appointment.
However, if the symptom is getting worse, becomes severe, or includes warning signs like heavy bleeding, chest pain, severe headache, shortness of breath, or sudden leg swelling, contact your healthcare provider right away or seek urgent care.
16 symptoms you shouldn’t ignore when using Premarin cream
These reactions may signal a complication that needs evaluation.
1. Postmenopausal vaginal bleeding that is new, persistent, or recurring
Light spotting can occur with Premarin use, especially early. But if bleeding escalates or keeps returning, it should be evaluated. MedlinePlus warns that vaginal bleeding after menopause can be a sign of endometrial cancer in people with a uterus using estrogen.
Estrogen naturally makes the uterine lining thicken. Normally, progesterone balances this effect and helps shed the lining during a menstrual cycle. After menopause, if someone takes estrogen alone (without progesterone), the lining can keep building up.
Over time, this overgrowth can lead to endometrial hyperplasia, a thickened uterine lining, which can sometimes develop into endometrial cancer if not treated. That is why women who still have a uterus are usually prescribed both estrogen and progesterone, and not estrogen alone.
In a 52-week clinical trial using 0.5 g Premarin Vaginal Cream alone, inserted twice weekly or daily for 21 days, then off for 7 days, there was no evidence of endometrial hyperplasia or endometrial carcinoma.
2. Pelvic pain or pressure that is persistent or worsening
Pelvic pain is a reported adverse reaction in trials and postmarketing reports. But persistent pelvic pain can sometimes be linked to problems involving the uterus (such as fibroids, endometrial changes, or infection) or the ovaries (such as cysts or, rarely, tumors).
Because several different conditions can cause similar symptoms, persistent pain should be checked by a healthcare provider. This usually means:
-
- Lasting more than 2 to 3 weeks without improvement, or
- Recurring regularly over several cycles, or
- Continuing beyond 6 weeks, even if mild
In medical terms, pelvic pain that lasts 3 months or longer is considered chronic pelvic pain.
3. A new breast lump, nipple discharge that is bloody, or a breast change that worries you
Estrogen can stimulate breast tissue because breast cells contain estrogen receptors. This stimulation may cause temporary breast tenderness or fullness, especially when starting therapy. However, a new lump, thickening, skin dimpling, nipple inversion, or bloody discharge is not considered a routine medication effect.
These changes can occur when breast cells grow abnormally, when ducts become blocked or inflamed, or in rare cases when a tumor develops. Bloody discharge is concerning because it may signal changes inside a milk duct, including ductal growths that require imaging.
While most breast lumps are benign, any new or persistent change should be evaluated with a clinical exam and imaging to rule out serious conditions and ensure early detection if treatment is needed.
4. Chest pain, pressure, or tightness, especially with nausea, sweating, or shortness of breath
Premarin cream is applied vaginally, and the amount of estrogen that reaches the bloodstream is much lower than with pills. However, some amounts are still absorbed, and estrogen can affect blood clots by influencing the body’s clotting system and blood vessel function.
Here’s how:
-
- It increases certain clotting factors – Estrogen stimulates the liver to produce more clotting proteins, such as fibrinogen and factors VII, VIII, IX, and X. These proteins help blood clot more easily. Higher levels can shift the balance toward clot formation.
-
- It reduces natural anticoagulants – Estrogen can lower levels of natural “anti-clotting” proteins such as protein S and can reduce the body’s sensitivity to activated protein C, which normally helps prevent excessive clotting.
-
- It affects fibrinolysis – Estrogen can alter how the body breaks down clots by influencing plasminogen and tissue plasminogen activator (tPA), which may reduce clot breakdown in some settings.
With oral estrogen, this effect is stronger because it passes through the liver first, but even vaginal estrogen carries labeling warnings out of caution.
When clotting balance shifts toward formation, the risk of conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE) can increase, especially in people with other risk factors such as smoking, obesity, genetic clotting disorders, or prolonged immobility.
A heart attack happens when a blood clot blocks blood flow in one of the heart’s arteries. Symptoms can feel like pressure, squeezing, or heaviness in the chest, sometimes spreading to the arm, jaw, or back, and may come with nausea, cold sweating, or shortness of breath.
If they occur, seek emergency care right away. Do not wait to see if they improve.
5. A painful, swollen leg or calf, with warmth and redness on one side
These symptoms can signal a deep vein thrombosis (DVT), which is a blood clot that forms in a deep vein, usually in the leg.
The risk is higher if you have certain factors, such as:
-
- a personal or family history of blood clots
- obesity
- smoking
- recent surgery
- inherited clotting disorders like Factor V Leiden
A DVT often causes one-sided swelling, calf pain that may worsen when walking, warmth, or redness. The danger is that part of the clot can break off and travel to the lungs, causing a pulmonary embolism, which can be life-threatening.
So, even though large studies suggest low-dose vaginal estrogen carries a low clot risk, any sudden one-sided leg swelling or pain should be evaluated urgently.
6. One-sided weakness, face droop, trouble speaking, or sudden confusion
These are classic warning signs of a stroke, which happens when blood flow to part of the brain is blocked by a clot or when a blood vessel ruptures. As mentioned earlier, estrogen can slightly increase the risk of clot-related events in certain women.
Recent research provides reassuring data. In a nationwide study of 56,642 women with a prior ischemic stroke, including 3,353 women who experienced a second stroke, use of vaginal estradiol tablets was not associated with an increased risk of recurrent stroke. Even current users had no elevated risk.
That said, stroke symptoms often appear suddenly and always require emergency care. If you notice sudden one-sided weakness, facial droop, slurred speech, vision changes, or confusion, call emergency services immediately. Early treatment can significantly reduce long-term brain damage.
7. A sudden new severe headache, especially if it feels different from your usual headaches
The patient information for Premarin cream advises reporting a sudden, intense headache right away, especially if it is new, unusual, or the worst headache you have experienced.
While mild headaches can occur with hormone changes, a sudden severe headache can sometimes signal a serious problem, such as a stroke or bleeding in the brain. This is particularly important if you have migraine with aura, high blood pressure, smoking history, diabetes, high cholesterol, or other vascular risk factors, since these conditions already increase stroke risk.
If the headache comes on abruptly, is accompanied by vision changes, weakness, confusion, stiff neck, or difficulty speaking, seek emergency care immediately.
8. Vision changes, including sudden partial vision loss, new blind spots, or severe eye pain
Sudden changes in vision are never something to ignore.
The prescribing information for estrogen therapy includes warnings about visual abnormalities, and there have been rare postmarketing reports of retinal vascular thrombosis, which is a blood clot in the vessels of the eye. A clot in the retinal artery or vein can reduce or block blood flow to the retina, leading to sudden vision loss, blurred vision, dark spots, or a curtain-like shadow over part of your visual field.
If you suddenly lose part or all of your vision, develop bulging of one eye, double vision, or a severe migraine-like headache, stop using the medication and get checked by a doctor right away.
If the eye exam shows swelling of the optic nerve (papilledema) or damage to the retinal blood vessels, estrogen should not be restarted.
9. Yellowing of the skin or eyes, dark urine, or intense itching with fatigue
These symptoms can signal a liver problem. Estrogen therapy, including Premarin, carries warnings about hepatic impairment and cholestatic jaundice, a condition where bile flow from the liver becomes blocked. When bile builds up, it can cause:
-
- yellowing of the skin or eyes (jaundice)
- tea-colored urine
- pale stools
- itching without a rash
- unusual tiredness
Liver issues can sometimes start subtly, with mild fatigue or itching before visible yellowing appears. Although serious liver complications are uncommon, these symptoms should not be ignored. If you notice them, stop the medication and contact your healthcare provider promptly for blood tests to check liver function.
10. Severe upper right abdominal pain, fever, or nausea that feels like an attack
Sharp pain in the upper right side of your abdomen, especially if it comes on suddenly and feels intense, can be a sign of a gallbladder problem. Research has shown a 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogen therapy.
A gallbladder attack often causes pain that may spread to the back or right shoulder and can be accompanied by nausea, vomiting, or fever. Estrogen can increase cholesterol concentration in bile, which may promote gallstone formation.
Although the overall risk with low-dose vaginal estrogen appears lower than with oral therapy, severe abdominal pain like this should be evaluated promptly, especially if it is new or worsening.
11. Swelling of the lips, tongue, or face, or hives with throat tightness
An allergic reaction can cause rapid swelling of soft tissues and may lead to throat tightness, difficulty breathing, dizziness, or a drop in blood pressure. This can become life-threatening if the airway becomes blocked.
If you experience swelling of the face or throat, trouble breathing, or widespread hives, seek emergency care immediately and do not use the medication again unless cleared by a healthcare professional.
12. Severe vaginal burning, swelling, or rash that makes it hard to tolerate the medication
Mild burning, itching, or irritation can occur when starting Premarin cream, especially if the vaginal tissue is already thin and sensitive after menopause. This discomfort is often temporary and improves as the tissue adapts and heals. However, intense burning, marked swelling, a spreading rash, or pain that worsens instead of easing is not typical.
More severe reactions may be due to sensitivity to one of the ingredients, a stronger inflammatory response, or a vaginal infection such as yeast or bacterial overgrowth.
If symptoms are severe, persist beyond a few days, or make it difficult to continue treatment, stop using the cream and contact your healthcare provider for further evaluation and guidance.
13. Discharge that turns foul-smelling, green, or yellow, or comes with fever or pelvic pain
A mild increase in vaginal discharge, called leukorrhea, can occur with estrogen therapy as the vaginal tissue becomes healthier and more hydrated. Clinical trial data also show that vaginitis has been reported in some users. However, discharge that has a strong or unpleasant odor, turns green or yellow, or is accompanied by fever or significant pelvic pain is not part of the normal adjustment period.
These symptoms may indicate a bacterial infection, yeast infection, or a sexually transmitted infection, all of which require proper evaluation and treatment. If you notice these changes, contact your healthcare provider, especially if pain or fever is present.
14. Yeast infection symptoms that keep coming back or do not improve
Vaginal yeast infections, also called vaginal candidiasis or moniliasis, have been reported in clinical trials and postmarketing data with estrogen therapy. Symptoms can include itching, thick white discharge, redness, and irritation. While occasional yeast infections can happen, repeated episodes or symptoms that do not improve with standard treatment may require further evaluation.
Estrogen changes the vaginal environment, which may sometimes affect yeast balance in susceptible individuals. If infections recur during therapy, your clinician may review your dosing schedule, assess for contributing factors such as diabetes or antibiotic use, or determine whether the symptoms are due to another condition that mimics a yeast infection.
15. Painful urination with fever, flank pain, or feeling very unwell
Burning during urination, called dysuria, and urinary tract infections have been reported in clinical trials of estrogen therapy. A simple bladder infection usually causes burning, urgency, and frequent urination without severe systemic symptoms. However, if urination is painful and you also develop fever, chills, nausea, back or side pain near the ribs, or feel generally very unwell, the infection may have spread to the kidneys.
Kidney infections are more serious and require prompt medical treatment. If these symptoms occur, contact your healthcare provider right away.
16. Fast swelling, sudden weight gain from fluid, or hypertension symptoms
Estrogen therapy has been associated with fluid retention and swelling, and elevated blood pressure appears in safety warnings. Some women may notice mild ankle swelling or slight weight changes, but rapid swelling of the legs, hands, or face, or gaining several pounds over a short period from fluid buildup, is not typical.
Estrogen can influence how the body handles salt and water and may affect blood vessel tone in susceptible individuals. If swelling develops quickly, is accompanied by shortness of breath, chest discomfort, or if you experience a severe headache with very high blood pressure readings, seek medical care promptly. These symptoms require evaluation to rule out serious complications.
Bottom line
Most side effects of Premarin cream are mild, such as vaginal discharge, breast tenderness, and headache, and are often manageable. However, don’t ignore red-flag symptoms like unusual bleeding, blood clot signs, chest pain, or allergic reactions. Long-term low-dose vaginal estrogen has been shown to be generally safe with minimal endometrial or cancer risk, but vigilance is important.
If in doubt about any new symptom while on Premarin cream, contact your healthcare provider for guidance. They can help determine if it’s a temporary adjustment or a warning you shouldn’t ignore.
Frequently Asked Questions
Sources
Dorr, M. B., Nelson, A. L., Mayer, P. R., Ranganath, R. P., Norris, P. M., Helzner, E. C., & Preston, R. A. (2010). Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertility and Sterility, 94(6), 2365–2368. https://doi.org/10.1016/j.fertnstert.2010.03.076
Crandall, C. J., Hovey, K. M., Andrews, C. A., Chlebowski, R. T., Stefanick, M. L., Lane, D. S., Shifren, J., Chen, C., Kaunitz, A. M., Cauley, J. A., & Manson, J. E. (2017). Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause the Journal of the North American Menopause Society, 25(1), 11–20. https://doi.org/10.1097/gme.0000000000000956
Haddadan, K. G., Eckert-Lind, C., Meaidi, A., Johansen, N. D., Lassen, M. C. H., Skaarup, K. G., Jensen, J. U. S., Torp-Pedersen, C., Gislason, G., Biering-Sørensen, T., & Modin, D. (2025). Recurrent ischemic stroke and vaginal estradiol in women with prior ischemic Stroke: a Nationwide Nested Case-Control Study. Stroke, 56(10), 2888–2894. https://doi.org/10.1161/strokeaha.125.050986
Pharmacy Times – Pharmacy Practice News and Expert Insights. (2026, February 13). FDA approves drug labeling changes to 6 menopausal hormone therapy products. Pharmacy Times – Pharmacy Practice News and Expert Insights. https://www.pharmacytimes.com/view/fda-approves-drug-labeling-changes-to-6-menopausal-hormone-therapy-products
FDA. (2026, February 12). FDA approves labeling changes to menopausal hormone therapy products. U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
Cho, L., Kaunitz, A. M., Faubion, S. S., Hayes, S. N., Lau, E. S., Pristera, N., Scott, N., Shifren, J. L., Shufelt, C. L., Stuenkel, C. A., & Lindley, K. J. (2023). Rethinking Menopausal hormone therapy: For whom, what, when, and how long? Circulation, 147(7), 597–610. https://doi.org/10.1161/circulationaha.122.061559
Lobo, R. A., Pickar, J. H., Stevenson, J. C., Mack, W. J., & Hodis, H. N. (2016). Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis, 254, 282–290. https://doi.org/10.1016/j.atherosclerosis.2016.10.005
Makary, M. A., Nguyen, C. P., Høeg, T. B., & Tidmarsh, G. F. (2025). Updated labeling for menopausal hormone therapy. JAMA, 335(2), 117. https://doi.org/10.1001/jama.2025.22259
